A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
← catalyst calendarSponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
4actual
Sites
2
Country
South Africa
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-11 | actual | When the study began enrolling |
| Primary completion | 2026-07-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-01 | actual | The whole study's end, after follow-up |
| First posted | 2026-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- B-ALL
- Leukemia
Intervention
- Drug: CD19 t-haNK
Primary outcome
what the primary-completion date above is the date OFEvaluate safety of CD19 t-haNK as a single agent in participants with selected CD19+ relapsed B-ALL.
measured up to 12 months post last dose of study drug
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed